ACLX Arcellx, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Arcellx, Inc. (ACLX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 28, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Arcellx, Inc. (ACLX) (SEC CIK 1786205), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Clinical-stage biotech developing novel D-Domain powered CAR-T immunotherapies for cancer and autoimmune diseases
- • New emphasis: ARC-SparX universal CAR-T platform and expanded non-oncology trials including Phase 1 generalized Myasthenia Gravis (gMG) dosing in 2025
Risk Factors
- • Regulatory risk: Hart-Scott-Rodino Antitrust Act clearance required for Gilead merger, with timing and approval uncertainty risking deal abandonment
- • Macroeconomic risk: Global pandemics and U.S. trade policy changes may disrupt operations and third-party providers critical to business
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • No revenue or profitability data disclosed in this section
- • No segment or product line performance details provided
Risk Factors
- • New FDA clinical hold risk on anito-cel triggered by previous partial hold requires costly and time-consuming mitigation measures
- • Net loss $170.8M for nine months ended Sept 30, 2025 vs $60.3M prior year, reflecting increased R&D and operational costs
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Arcellx merger agreement announced Feb 23, 2026 alongside FDA acceptance of BLA for anito-cel
- • Anito-cel targets BCMA for relapsed/refractory multiple myeloma — BLA acceptance signals regulatory review underway
Item 1.01: Entry into a Material Definitive Agreement
- • Gilead Sciences acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, totaling up to $120.00/share
- • CVR pays $5.00 only if anito-cel cumulative worldwide sales exceed $6.0B by December 31, 2029 — milestone is high-bar, payment not guaranteed
Annual Reports Archive10-K
AI-powered analysis of Arcellx, Inc. (ACLX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Arcellx, Inc. (ACLX) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Arcellx, Inc. (ACLX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Profitability | |||||
| Revenue | — | — | $110.3M | $107.9M | $22.3M |
| Operating Income | — | -$191.3M | -$89.9M | -$137.6M | -$253.1M |
| Net Income | -$65.0M | -$188.7M | -$70.7M | -$107.3M | -$228.9M |
| Op. Margin | — | — | -81.5% | -127.5% | -1135.6% |
| Net Margin | — | — | -64.1% | -99.5% | -1027.3% |
| Balance Sheet | |||||
| Total Assets | — | $313.8M | $825.1M | $711.3M | $604.0M |
| Equity | — | $205.0M | $485.4M | $454.8M | $402.4M |
| ROE | — | -92.1% | -14.6% | -23.6% | -56.9% |
Source: XBRL financial data from Arcellx, Inc. (ACLX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 28, 2026 | — | — | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 23, 2026 | — | Analysis | — |
8-K | Dec 8, 2025 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Aug 14, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Mar 29, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 14, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 15, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 24, 2022 | Dec 31, 2021 | — |
Frequently Asked Questions
What are the latest ACLX SEC filings in 2026?
Arcellx, Inc. (ACLX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ACLX file its most recent 10-K annual report?
Arcellx, Inc. (ACLX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ACLX 10-Q quarterly reports?
Arcellx, Inc. (ACLX)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every ACLX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ACLX filed recently?
Arcellx, Inc. (ACLX)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ACLX insider trading activity (Form 4)?
SignalX aggregates every ACLX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ACLX file with the SEC?
Arcellx, Inc. (ACLX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ACLX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Arcellx, Inc. (ACLX).
What is ACLX's SEC CIK number?
Arcellx, Inc. (ACLX)'s SEC CIK (Central Index Key) number is 1786205. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1786205 to look up all ACLX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ACLX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Arcellx, Inc. (ACLX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Arcellx, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 19+ filings.